University of Dundee the Interaction of Hypotaurine and Other Sulfinates
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Acetyl-Coa Synthetase 3 Promotes Bladder Cancer Cell Growth Under Metabolic Stress Jianhao Zhang1, Hongjian Duan1, Zhipeng Feng1,Xinweihan1 and Chaohui Gu2
Zhang et al. Oncogenesis (2020) 9:46 https://doi.org/10.1038/s41389-020-0230-3 Oncogenesis ARTICLE Open Access Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress Jianhao Zhang1, Hongjian Duan1, Zhipeng Feng1,XinweiHan1 and Chaohui Gu2 Abstract Cancer cells adapt to nutrient-deprived tumor microenvironment during progression via regulating the level and function of metabolic enzymes. Acetyl-coenzyme A (AcCoA) is a key metabolic intermediate that is crucial for cancer cell metabolism, especially under metabolic stress. It is of special significance to decipher the role acetyl-CoA synthetase short chain family (ACSS) in cancer cells confronting metabolic stress. Here we analyzed the generation of lipogenic AcCoA in bladder cancer cells under metabolic stress and found that in bladder urothelial carcinoma (BLCA) cells, the proportion of lipogenic AcCoA generated from glucose were largely reduced under metabolic stress. Our results revealed that ACSS3 was responsible for lipogenic AcCoA synthesis in BLCA cells under metabolic stress. Interestingly, we found that ACSS3 was required for acetate utilization and histone acetylation. Moreover, our data illustrated that ACSS3 promoted BLCA cell growth. In addition, through analyzing clinical samples, we found that both mRNA and protein levels of ACSS3 were dramatically upregulated in BLCA samples in comparison with adjacent controls and BLCA patients with lower ACSS3 expression were entitled with longer overall survival. Our data revealed an oncogenic role of ACSS3 via regulating AcCoA generation in BLCA and provided a promising target in metabolic pathway for BLCA treatment. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction acetyl-CoA synthetase short chain family (ACSS), which In cancer cells, considerable number of metabolic ligates acetate and CoA6. -
3-Iodo-Alpha-Methyl-L- Tyrosine
A Strategyfor the Study of CerebralAmino Acid Transport Using Iodine-123-Labeled Amino Acid Radiopharmaceutical: 3-Iodo-alpha-methyl-L- tyrosine Keiichi Kawai, Yasuhisa Fujibayashi, Hideo Saji, Yoshiharu Yonekura, Junji Konishi, Akiko Kubodera, and Akira Yokoyama Faculty ofPharmaceutical Sciences, Science Universityof Tokyo, Tokyo, Japan and School ofMedicine and Faculty of Pharmaceutical Sciences, Kyolo University, Kyoto, Japan In the present work, a search for radioiodinated tyrosine We examined the brain accumulation of iodine-i 23-iodo-al derivatives for the cerebral tyrosine transport is attempted. pha-methyl-L-tyrosine (123I-L-AMT)in mice and rats. l-L-AMT In the screening process, in vitro accumulation studies in showed high brain accumulation in mice, and in rats; rat brain rat brain slices, measurement ofbrain uptake index (BUI), uptake index exceeded that of 14C-L-tyrosine.The brain up and in vivo mouse biodistribution are followed by the take index and the brain slice studies indicated the affinity of analysis of metabolites. In a preliminary study, the radio l-L-AMT for earner-mediatedand stereoselective active trans iodinated monoiodotyrosine in its L- and D-form (L-MIT port systems, respectively; both operating across the blood and D-MIT) and its noniodinated counterpart (‘4C-L- brain barrier and cell membranes of the brain. The tissue tyrosine) are tested. homogenate analysis revealed that most of the accumulated radioactivity belonged to intact l-L-AMT, an indication of its The initial part of the work provided the basis for a stability. Thus, 1231-L-AMTappears to be a useful radiophar radioiodinated tyrosine derivative to be used for the meas maceutical for the selective measurement of cerebral amino urement of cerebral tyrosine transport. -
Oxidative Stress and Inflammation in Hepatic Diseases
Review Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine Kívia Queiroz de Andrade 1, Fabiana Andréa Moura 1,2, John Marques dos Santos 3, Orlando Roberto Pimentel de Araújo 3, Juliana Célia de Farias Santos 2 and Marília Oliveira Fonseca Goulart 3,* Received: 10 October 2015; Accepted: 4 December 2015; Published: 18 December 2015 Academic Editor: Guido Haenen 1 Pós Graduação em Ciências da Saúde (PPGCS), Campus A. C. Simões, Tabuleiro dos Martins, 57072-970 Maceió, AL, Brazil; [email protected] (K.Q.A.); [email protected] (F.A.M.) 2 Faculdade de Nutrição/Universidade Federal de Alagoas (FANUT/UFAL), Campus A. C. Simões, Tabuleiro dos Martins, 57072-970 Maceió, AL, Brazil; [email protected] 3 Instituto de Química e Biotecnologia (IQB), Universidade Federal de Alagoas (UFAL), Campus A. C. Simões, Tabuleiro dos Martins, 57072-970 Maceió, AL, Brazil; [email protected] (J.M.S.); [email protected] (O.R.P.A.) * Correspondence: [email protected]; Tel.: +55-82-98818-0463 Abstract: Liver disease is highly prevalent in the world. Oxidative stress (OS) and inflammation are the most important pathogenetic events in liver diseases, regardless the different etiology and natural course. N-acetyl-L-cysteine (the active form) (NAC) is being studied in diseases characterized by increased OS or decreased glutathione (GSH) level. NAC acts mainly on the supply of cysteine for GSH synthesis. The objective of this review is to examine experimental and clinical studies that evaluate the antioxidant and anti-inflammatory roles of NAC in attenuating markers of inflammation and OS in hepatic damage. -
Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients
bioRxiv preprint doi: https://doi.org/10.1101/416396; this version posted September 13, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients Running title – Increased cysteine and glucose metabolism in sALS cases Qiuying Chen, PhD1*, Davinder Sandhu, M.S.1*, Csaba Konrad, PhD2, Dipa Roychoudhury, PhD3, Benjamin I. Schwartz1, Roger R. Cheng1, Kirsten Bredvik2, Hibiki Kawamata, PhD2, Elizabeth L. Calder, PhD4, Lorenz Studer, MD4, Steven. M. Fischer3, Giovanni Manfredi MD/PhD2* and Steven. S. Gross, PhD1* *Joint first/senior authors 1Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA 2Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA 3Agilent Technology, Santa Clara, CA, USA 4The Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Center, New York, NY. Keywords: sporadic amyotrophic lateral sclerosis, metabolomics, stable isotope tracing, trans-sulfuration, hypermetabolism, disease stratification, energy metabolism Co-Corresponding Authors: Steven S. Gross, PhD Department of Pharmacology Weill Cornell Medicine Phone: 212-746-6257 Email: [email protected] Giovanni Manfredi, MD/PhD Brain and Mind Research Institute Weill Cornell Medicine Phone: 646-962-8172 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/416396; this version posted September 13, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Number of characters: Title --- 94 Running head---48 Number of words: Title --- 13 Running head --- 8 Abstract---232 Introduction --- 549 Discussion --- 1126 Body of manuscript --- 5706 Number of figures: 8 Number of color figures: 8 Number of tables:1 2 bioRxiv preprint doi: https://doi.org/10.1101/416396; this version posted September 13, 2018. -
Nucleotides and Nucleic Acids
Nucleotides and Nucleic Acids Energy Currency in Metabolic Transactions Essential Chemical Links in Response of Cells to Hormones and Extracellular Stimuli Nucleotides Structural Component Some Enzyme Cofactors and Metabolic Intermediate Constituents of Nucleic Acids: DNA & RNA Basics about Nucleotides 1. Term Gene: A segment of a DNA molecule that contains the information required for the synthesis of a functional biological product, whether protein or RNA, is referred to as a gene. Nucleotides: Nucleotides have three characteristic components: (1) a nitrogenous (nitrogen-containing) base, (2) a pentose, and (3) a phosphate. The molecule without the phosphate groups is called a nucleoside. Oligonucleotide: A short nucleic acid is referred to as an oligonucleotide, usually contains 50 or fewer nucleotides. Polynucleotide: Polymers containing more than 50 nucleotides is usually referred to as polynucleotide. General structure of nucleotide, including a phosphate group, a pentose and a base unit (either Purine or Pyrimidine). Major purine and Pyrimidine bases of nucleic acid The roles of RNA and DNA DNA: a) Biological Information Storage, b) Biological Information Transmission RNA: a) Structural components of ribosomes and carry out the synthesis of proteins (Ribosomal RNAs: rRNA); b) Intermediaries, carry genetic information from gene to ribosomes (Messenger RNAs: mRNA); c) Adapter molecules that translate the information in mRNA to proteins (Transfer RNAs: tRNA); and a variety of RNAs with other special functions. 1 Both DNA and RNA contain two major purine bases, adenine (A) and guanine (G), and two major pyrimidines. In both DNA and RNA, one of the Pyrimidine is cytosine (C), but the second major pyrimidine is thymine (T) in DNA and uracil (U) in RNA. -
Supplemental Table 1. Differences in Fasting Metabolites (All) by CKD Status in Plasma
Supplemental table 1. Differences in fasting metabolites (all) by CKD status in plasma. Metabolites in bold show hits controlling FDR at 10%, in a model that controls for age, sex, race (white versus not), and weight. Ordered by subclasses of metabolites followed by adjusted percent difference between CKD and controls and adjusted p-value for difference. Metabolite % Difference p-value q-value Pathway in CKD, compared with controls Cystine (241.1 / 120.0) 33 2.60E-09 1.52E-08 Amino Acid Proline (116.1 / 70.0) 20 0.000195 0.000692 Amino Acid 2-Hydroxyisovaleric Acid (117.0 / 71.0) 47 0.000331 0.001139 Amino Acid Tyrosine (182.1 / 136.0) -13 0.000633 0.002014 Amino Acid Serine (106.0 / 60.0) -8 0.029507 0.065132 Amino Acid Glycine (76.0 / 30.1) 13 0.032003 0.06842 Amino Acid Leucine (132.1 / 86.0) -5 0.067499 0.139499 Amino Acid 5-Aminovaleric Acid (118.0 / 55.0) -4 0.127339 0.253324 Amino Acid Threonine (120.1 / 74.0 (2)) -7 0.145125 0.281179 Amino Acid Glutamine (147.1 / 84.0) 3 0.169291 0.318061 Amino Acid Valine (118.1 / 72.0) -4 0.201091 0.36138 Amino Acid Arginine (175.1 / 70.0) 5 0.209045 0.362752 Amino Acid Sarcosine (89.9 / 44.0) -7 0.209395 0.362752 Amino Acid Cadaverine (103.0 / 86.0) 4 0.281896 0.459935 Amino Acid Histidine (156.1 / 110.0) 3 0.319987 0.495386 Amino Acid Alanine (90.0 / 44.0) 5 0.330111 0.499193 Amino Acid iso-Leucine (132.1 / 86.0 (2)) -3 0.336431 0.50262 Amino Acid Phenylalanine (166.1 / 120.0) 2 0.461445 0.61526 Amino Acid Methionine (150.1 / 61.0) -3 0.516557 0.681415 Amino Acid Pipecolate (130.0 / 84.0) -2 -
Taurine Supplementation Improves the Utilization of Sulfur
Available online at www.sciencedirect.com Journal of Nutritional Biochemistry 20 (2009) 132–139 Taurine supplementation improves the utilization of sulfur-containing amino acids in rats continually administrated alcohol Hui-Ting Yanga, Yi-Wen Chienb, Jen-Horng Tsenc, Ching-Chien Changb,d, ⁎ ⁎ Jer-Hwa Change, ,1, Shih-Yi Huangb, ,1 aSchool of Pharmaceutical Science, Taipei Medical University, Taipei bSchool of Nutrition and Health Sciences, Taipei Medical University, Taipei cSchool of Nutrition, China Medical University, Taichung, Taiwan dGeneral Education Center, Northern Taiwan Institute of Science and Technology, Taipei eDepartment of Internal Medicine, Taipei Medical University Wan Fang Hospital, Taipei, Taiwan Received 27 September 2007; received in revised form 18 December 2007; accepted 4 January 2008 Abstract The main purpose of this study was to evaluate changes in brain sulfur-containing amino acid (SCAA) metabolism to determine whether taurine intervened under continuous alcohol intake. We fed 80 male Sprague–Dawley rats 30% alcohol-containing water for 4 weeks. Eighty animals were divided into two groups (with or without 2 g/kg body weight taurine supplementation), and five were killed every week in each group for monitoring SCAA changes in the brain, liver, kidneys and heart. Results indicated that the plasma alcohol concentration increased from Weeks 1–4; however, animals with taurine supplementation showed a lower plasma concentration of ethanol in Week 2. As to SCAA concentrations, cysteine and taurine were both lower after a week of alcohol ingestion in the brain and plasma; the same declining trend was shown in the liver in Week 2. In contrast, plasma and hepatic concentrations of homocysteine were elevated in Week 2, and the plasma S-adenosylmethionine (SAM)/S-adenosylhomocysteine (SAH) ratio also decreased in Week 1. -
Combined Metabolic Activators Improve Cognitive Functions Without Altering Motor
medRxiv preprint doi: https://doi.org/10.1101/2021.07.28.21261293; this version posted August 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease Burak Yulug1,#, Ozlem Altay2,#, Xiangyu Li2, #, Lutfu Hanoglu3, Seyda Cankaya1, Simon Lam4, Hong Yang2, Ebru Coskun3, Ezgi İdil1, Rahim Nogaylar1, Ahmet Hacımuftuoglu5, Muhammad Arif2, Saeed Shoaie2,4, Cheng Zhang2.6, Jens Nielsen7, Hasan Turkez8, Jan Borén9, Mathias Uhlén2,*, Adil Mardinoglu2,4,* 1Department of Neurology and Neuroscience, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey 2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden 3Department of Neurology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey 4Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King’s College London, London, United Kingdom 5Department of Medical Pharmacology, Faculty of Medicine, Atatürk University, Erzurum, Turkey. 6School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China 7Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden 8Department of Medical Biology, Faculty of Medicine, Atatürk University, Erzurum, Turkey 9Department -
The Biosynthesis Reaction of Hypotaurine to Taurine
UNIVERSITY OF CENTRAL OKLAHOMA Edmond, Oklahoma Jackson College of Graduate Studies The Biosynthesis Reaction of Hypotaurine to Taurine A THESIS SUBMITTED TO THE GRADUATE FACULTY In partial fulfillment of the requirements For the degree of MASTER OF SCIENCE IN BIOLOGY By Roxanna Q. Grove Edmond, Oklahoma 2018 Acknowledgments Working on this project has been a period of intense learning for me, not only in the scientific arena, but also on a personal level. Writing this thesis has had a significant impact on me. I would like to reflect on people who have been supported and helped me so much throughout this period. First of all, I would like to express my gratitude toward my advisor, Dr. Steven J. Karpowicz, for his devotion, inspiration, and guidance. I am so grateful to have the opportunity to work with such an intelligent, dedicated, and patient professor. I appreciate his vast knowledge and skills in many areas such as biochemistry, genetics, and bioinformatics, and his assistance in writing this thesis. I would like to thank the other members of my committee, Dr. Nikki Seagraves, Dr. Hari Kotturi, and Dr. Lilian Chooback, for their guidance, support, and for providing materials throughout this project. An exceptional thanks go to Dr. John Bowen of the Department of Chemistry for advice in the analytical laboratory and Dr. Susan L. Nimmo from the Department of Chemistry and Biochemistry at the University of Oklahoma for assistance with NMR. This project was supported by funding from the College of Mathematics and Science and a Research, Creative, and Scholarly Activities (RCSA) grant from the Office of High Impact Practices at UCO. -
Cysteamine: an Old Drug with New Potential
Drug Discovery Today Volume 18, Numbers 15/16 August 2013 REVIEWS POST SCREEN Cysteamine: an old drug with new potential Reviews 1,2 3 1,2,4 Martine Besouw , Rosalinde Masereeuw , Lambert van den Heuvel and 1,2 Elena Levtchenko 1 Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium 2 Laboratory of Pediatrics, Department of Development & Regeneration, Catholic University Leuven, Belgium 3 Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands 4 Laboratory for Genetic, Endocrine and Metabolic Disorders, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Cysteamine is an amino thiol with the chemical formula HSCH2CH2NH2. Endogenously, cysteamine is derived from coenzyme A degradation, although its plasma concentrations are low. Most experience with cysteamine as a drug originates from the field of the orphan disease cystinosis, in which cysteamine is prescribed to decrease intralysosomal cystine accumulation. However, over the years, the drug has been used for several other applications both in vitro and in vivo. In this article, we review the different applications of cysteamine, ending with an overview of ongoing clinical trials for new indications, such as neurodegenerative disorders and nonalcoholic fatty liver disease (NAFLD). The recent development of an enteric-coated cysteamine formulation makes cysteamine more patient friendly and will extend its applicability for both old and new indications. Endogenous cysteamine production cysteine, it is oxidized into taurine by hypotaurine dehydrogenase Cysteamine (synonyms: b-mercaptoethylamine, 2-aminoetha- (Fig. 1b). Taurine is excreted either in urine, or in feces in the form nethiol, 2-mercaptoethylamine, decarboxycysteine, thioethano- of bile salts [3]. -
Omics in Myopia
Journal of Clinical Medicine Review Omics in Myopia Emil Tomasz Grochowski 1,* , Karolina Pietrowska 2 , Tomasz Kowalczyk 2, Zofia Mariak 1, Adam Kretowski 2,3, Michal Ciborowski 2,* and Diana Anna Dmuchowska 1,* 1 Department of Ophthalmology, Medical University of Bialystok, M. Sklodowskiej Curie 24a, 15-276 Bialystok, Poland; [email protected] 2 Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej Curie 24a, 15-276 Bialystok, Poland; [email protected] (K.P.); [email protected] (T.K.); [email protected] (A.K.) 3 Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, M. Sklodowskiej Curie 24a, 15-276 Bialystok, Poland * Correspondence: [email protected] (E.T.G.); [email protected] (M.C.); [email protected] (D.A.D.) Received: 8 October 2020; Accepted: 25 October 2020; Published: 28 October 2020 Abstract: Myopia is a globally emerging issue, with multiple medical and socio-economic burdens and no well-established causal treatment thus far. A better insight into altered biochemical pathways and underlying pathogenesis might facilitate early diagnosis and treatment of myopia, ultimately leading to the development of more effective preventive and therapeutic measures. In this review, we summarize current data about the metabolomics and proteomics of myopia in humans and present various experimental approaches and animal models, along with their strengths and weaknesses. We also discuss the potential applicability of these -
TITLE: Cysteine Catabolism: a Novel Metabolic Pathway Contributing To
Author Manuscript Published OnlineFirst on December 18, 2013; DOI: 10.1158/0008-5472.CAN-13-1423 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. TITLE: Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth AUTHORS: Antony Prabhu*1,2, Bhaswati Sarcar*1,2, Soumen Kahali1,2, Zhigang Yuan2, Joseph J. Johnson3, Klaus-Peter Adam5, Elizabeth Kensicki5, Prakash Chinnaiyan1,2,4 AFFILIATIONS: 1Radiation Oncology, 2Chemical Biology and Molecular Medicine, 3Advanced Microscopy Laboratory, 4Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 5Metabolon, Inc, Durham, NC, USA * Authors contributed equally to this work. CONFLICT OF INTEREST: E.K. and K.A are paid employees of Metabolon, Inc. RUNNING TITLE: The CSA/CDO regulatory axis in glioblastoma CONTACT: Prakash Chinnaiyan, MD Associate Member Radiation Oncology, Cancer Imaging and Metabolism H. Lee Moffitt Cancer Center and Research Institute 12902 Magnolia Drive Tampa, FL 33612 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2013 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 18, 2013; DOI: 10.1158/0008-5472.CAN-13-1423 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Office: 813.745.3425 Fax: 813.745.3829 Email: [email protected] 2 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2013 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 18, 2013; DOI: 10.1158/0008-5472.CAN-13-1423 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.